Stratus Medical Secures $10 Million for Advanced Pain Relief
February 10, 2026, 3:37 pm
Stratus Medical secured $10 million in Series B funding. Wasatch Health Partners led the round. The investment targets advanced radiofrequency (RF) ablation technology. It will fuel development of a new RF Generator and innovative basivertebral nerve ablation (BVNA) systems. Funds also support patent expansion and clinical studies. These efforts address vertebrogenic low back pain. Over five million Americans suffer from this chronic condition. Stratus Medical aims to deliver improved pain relief solutions.
Stratus Medical just raised $10 million. This Series B funding round strengthens its mission. It targets innovative radiofrequency (RF) ablation technology. Wasatch Health Partners led the investment. The capital fuels critical development. It advances a new Stratus Medical RF Generator. It pushes forward neurovasis basivertebral nerve ablation (BVNA) technology. Funds also secure patent portfolio expansion. A key clinical study will commence. These initiatives combat chronic pain.
Chronic low back pain affects millions. Vertebrogenic low back pain is a significant subset. Over five million Americans endure this condition. Damaged vertebral endplates cause this pain. Progressive degeneration often leads to it. Current treatments include medication. Physical therapy also helps. Basivertebral nerve ablation (BVNA) offers another option. Stratus Medical develops advanced solutions. It seeks to redefine chronic pain management.
Stratus Medical focuses on medical devices. Its core technology is RF ablation. This technique uses heat. It targets nerves. It disrupts pain signals. The company’s innovation reduces pain. It improves quality of life for patients. Continuous advancements mark its approach.
The new Stratus Medical RF Generator promises next-gen performance. Neurovasis BVNA technology represents a significant leap forward. These systems are still under development. They have not yet received FDA clearance. Evaluation by the U.S. Food and Drug Administration is pending. This crucial step precedes market availability. Stratus Medical prioritizes safety and efficacy.
Stratus Medical already impacts the market. Its NIMBUS system exemplifies this success. NIMBUS features a patented RF multitined expandable electrode design. It gains market share steadily. Physicians value its streamlined workflow. Performance claims are robust. NIMBUS reduces procedure times. It treats large-volume lesions effectively. Sustained pain relief is its primary goal. The design supports comprehensive ablation. This leads to better patient outcomes.
Wasatch Health Partners demonstrates strong belief. Their investment signals deep confidence. They previously provided a $25 million convertible debt facility. This solidified a long-term partnership. Wasatch's Growth Fund led the current round. Their commitment underscores Stratus Medical's potential. They see a future of significant impact.
Stratus Medical operates from Magnolia, Texas. The company stands as a recognized innovator. The Deloitte Technology Fast 500 lists its achievements. Pepperdine named it a Most Fundable Company. The Houston Business Journal also recognized its rapid growth. These accolades highlight its market position. They affirm its commitment to innovation.
The new funding accelerates product readiness. It fast-tracks clinical validation processes. Stratus Medical aims to deliver additional value to healthcare. Future RF technologies promise easier treatments. They offer faster procedures. They also present potential cost reductions for facilities. Hospitals stand to benefit. Ambulatory Surgery Centers (ASCs) also gain efficiencies. The company continues its fight against chronic pain. It seeks to redefine treatment standards. Innovation drives every pursuit. Stratus Medical moves closer to broader patient impact. Its advancements address a critical healthcare need. This funding propels its mission forward.
Stratus Medical just raised $10 million. This Series B funding round strengthens its mission. It targets innovative radiofrequency (RF) ablation technology. Wasatch Health Partners led the investment. The capital fuels critical development. It advances a new Stratus Medical RF Generator. It pushes forward neurovasis basivertebral nerve ablation (BVNA) technology. Funds also secure patent portfolio expansion. A key clinical study will commence. These initiatives combat chronic pain.
Chronic low back pain affects millions. Vertebrogenic low back pain is a significant subset. Over five million Americans endure this condition. Damaged vertebral endplates cause this pain. Progressive degeneration often leads to it. Current treatments include medication. Physical therapy also helps. Basivertebral nerve ablation (BVNA) offers another option. Stratus Medical develops advanced solutions. It seeks to redefine chronic pain management.
Stratus Medical focuses on medical devices. Its core technology is RF ablation. This technique uses heat. It targets nerves. It disrupts pain signals. The company’s innovation reduces pain. It improves quality of life for patients. Continuous advancements mark its approach.
The new Stratus Medical RF Generator promises next-gen performance. Neurovasis BVNA technology represents a significant leap forward. These systems are still under development. They have not yet received FDA clearance. Evaluation by the U.S. Food and Drug Administration is pending. This crucial step precedes market availability. Stratus Medical prioritizes safety and efficacy.
Stratus Medical already impacts the market. Its NIMBUS system exemplifies this success. NIMBUS features a patented RF multitined expandable electrode design. It gains market share steadily. Physicians value its streamlined workflow. Performance claims are robust. NIMBUS reduces procedure times. It treats large-volume lesions effectively. Sustained pain relief is its primary goal. The design supports comprehensive ablation. This leads to better patient outcomes.
Wasatch Health Partners demonstrates strong belief. Their investment signals deep confidence. They previously provided a $25 million convertible debt facility. This solidified a long-term partnership. Wasatch's Growth Fund led the current round. Their commitment underscores Stratus Medical's potential. They see a future of significant impact.
Stratus Medical operates from Magnolia, Texas. The company stands as a recognized innovator. The Deloitte Technology Fast 500 lists its achievements. Pepperdine named it a Most Fundable Company. The Houston Business Journal also recognized its rapid growth. These accolades highlight its market position. They affirm its commitment to innovation.
The new funding accelerates product readiness. It fast-tracks clinical validation processes. Stratus Medical aims to deliver additional value to healthcare. Future RF technologies promise easier treatments. They offer faster procedures. They also present potential cost reductions for facilities. Hospitals stand to benefit. Ambulatory Surgery Centers (ASCs) also gain efficiencies. The company continues its fight against chronic pain. It seeks to redefine treatment standards. Innovation drives every pursuit. Stratus Medical moves closer to broader patient impact. Its advancements address a critical healthcare need. This funding propels its mission forward.